Clinical Trials Sponsored by Janssen Inc.

Total 38313 results

Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Janssen Inc.

Completed

A Study of Participants With Advanced Prostate Cancer in Canada (GURC)

Prostatic Neoplasms

Canada
Janssen Inc.

Completed

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CanCARE)

Diabetes Mellitus, Type 2

Canada
Janssen Inc.

Completed

An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis (PROSTARRT)

Chronic Kidney Disease

Canada
Janssen Inc.

Completed

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (ICE)

Crohn's Disease

Canada
Janssen Inc.

Completed

Remicade Infusion Management Program (RemiTRAC)

Arthritis, Rheumatoid | Crohn Disease

Canada
Janssen Inc.

Completed

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting (COSMiC)

Prostatic Neoplasms

Canada
Janssen Inc.

Completed

Biologic Treatment Registry Across Canada (BioTRAC)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis, Axial

Canada
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Janssen Inc.

Terminated

Observational Study of Golimumab Intravenous Infusion (GO-IV)

Rheumatoid Arthritis

Canada
Janssen Inc.

Completed

Golimumab for Adherence in Rheumatoid Arthritis (GO FAR)

Arthritis, Rheumatoid

Canada
Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
Janssen Biotech, Inc.

Completed

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Rheumatoid Arthritis | Arthritis, Psoriatic | Ankylosing Spondylitis
Janssen Biotech, Inc.

Completed

The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry (TREAT)

Crohn's Disease
Janssen Biotech, Inc.

Active, not recruiting

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Ulcerative Colitis

United States, France, Germany, Spain, Canada, Greece, Korea, Republic of, Austria, Czechia
Janssen Biotech, Inc.

Active, not recruiting

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Prostate Cancer | Prostatic Neoplasm

United States
Janssen BioPharma, Inc.

Completed

A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

Healthy

United Kingdom
Janssen Biotech, Inc.

Completed

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States
Janssen Biotech, Inc.

Completed

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Psoriasis
Janssen Biotech, Inc.

Terminated

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) (REGAIN)

Arthritis, Rheumatoid

United States, Canada
Janssen Biotech, Inc.

Completed

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR)

Psoriasis

United States
Janssen Biotech, Inc.

Terminated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Crohn's Disease

United States, France, United Kingdom, Germany, Belgium, Australia, Israel, Canada, Netherlands, New Zealand, Czech Republic, Austria, Poland, Hungary
Janssen-Ortho Inc., Canada

Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Schizophrenia

Canada, United Kingdom, Australia, Ireland
Janssen-Ortho Inc., Canada

Completed

Impact of Tolerability Issues on Chronic Pain

Pain
Janssen-Ortho Inc., Canada

Completed

A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers

Pharmacokinetics
Janssen-Ortho Inc., Canada

Completed

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma
Janssen-Ortho Inc., Canada

Completed

An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method

Female Contraception
Janssen-Ortho Inc., Canada

Withdrawn

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Anemia | Blood Transfusion | Orthopedic Surgery
Janssen-Ortho Inc., Canada

Completed

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostate Neoplasms

Canada
Janssen-Ortho Inc., Canada

Completed

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Canada
Janssen-Ortho Inc., Canada

Completed

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Attention Deficit Disorder With Hyperactivity
Janssen-Ortho Inc., Canada

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Anemia
Janssen-Ortho Inc., Canada

Completed

An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans

Headache
Janssen-Ortho Inc., Canada

Completed

CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.

Depressive Disorder, Major
Janssen-Ortho Inc., Canada

Completed

An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children

Attention Deficit Hyperactivity Disorder
Janssen-Ortho Inc., Canada

Completed

A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder

Bipolar Disorder
Janssen-Ortho Inc., Canada

Terminated

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Multiple Myeloma

Canada
Janssen-Ortho Inc., Canada

Completed

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

GERD
Janssen-Ortho Inc., Canada

Completed

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Gastroesophageal Reflux | Heartburn
Janssen-Ortho Inc., Canada

Completed

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Anemia | Kidney Failure | Left Ventricular Hypertrophy
Janssen-Ortho Inc., Canada

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

Autistic Disorder | Developmental Disabilities | Rett Syndrome | Asperger Syndrome | DCild Development Disorders, Pervasive
Janssen-Ortho Inc., Canada

Completed

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

Schizophrenia
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
University of Calgary
Janssen Inc.

Completed

Prucalopride Versus Placebo in Gastroparesis

Diabetes Mellitus | Gastroparesis

Canada
Université de Sherbrooke
Janssen Inc.

Withdrawn

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF) (Canacardia)

Heart Failure | Type2 Diabetes
University of Calgary
Janssen Inc.

Completed

Infliximab IBD Influenza Vaccine Study

Inflammatory Bowel Disease

Canada
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis (SpA23)

Spondyloarthritis

France
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis (Pso23)

Psoriasis

France
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States

3

Subscribe